Efficacy and efficiency of gastric electrical stimulation with short pulses in the treatment of vasopressin-induced emetic responses in dogs.
The aim of this study was to determine the most effective and efficient anti-emetic parameters of short-pulse gastric electrical stimulation (GES) in dogs. Seven female beagle dogs implanted with four pairs of gastric electrodes were studied in eight randomized sessions (saline, vasopressin, and six GES sessions with different parameters). Each session consisted of four 20-min recordings of gastric slow waves and symptoms. In sessions 1 and 2, saline and vasopressin, respectively, were infused during the second 20-min period. The protocol of the other six sessions was the same as session 2 except that GES was continuously applied. It was found that: (1) vasopressin induced gastric dysrhythmia and emetic response (P < 0.01, anova); (2) short-pulse GES with a frequency of 14 or 40 Hz and pulse width of 0.1 or 0.3 ms, but not 0.6 ms was able to reduce symptoms induced by vasopressin; (3) short-pulse GES with a pulse width of 0.3 ms was the most effective in preventing vasopressin-induced symptoms; (4) none of the tested GES methods improved vasopressin-induced gastric dysrhythmia. We conclude that vasopressin induces gastric dysrhythmia and symptoms. Short-pulse GES with a pulse width of 0.3 ms and frequency of 14 Hz is most effective and efficient in preventing vasopressin-induced emetic responses in dogs.
Song
G
G
Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hou
X
X
Yang
B
B
Sun
Y
Y
Liu
J
J
Qian
W
W
Chen
J D Z
JD
D000818:Animals; D004285:Dogs; D004558:Electric Stimulation; D004567:Electrodes, Implanted; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects / Q000502:physiology; D016065:Myoelectric Complex, Migrating / Q000502:physiology; D013270:Stomach / Q000187:drug effects / Q000502:physiology*; D014662:Vasoconstrictor Agents / Q000009:adverse effects*; D014667:Vasopressins / Q000009:adverse effects*; D014839:Vomiting / Q000139:chemically induced / Q000628:therapy*
D014662:Vasoconstrictor Agents; D014667:Vasopressins